JOUNCE THERAPEUTICS, INC. (NASDAQ:JNCE) Files An 8-K Other Events
Item 8.01 Other Events.
a press release announcing the enrollment of patients into the
Phase 2 portion of the Companys Phase 1/2 ICONIC study of
JTX-2011. JTX-2011 is a monoclonal antibody targeting ICOS, a
protein found on the surface of certain T cells within many solid
tumors. A copy of the press released is attached as Exhibit 99.1
to this Current Report on Form 8-K and incorporated herein by
reference.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press release issued by Jounce Therapeutics, Inc. on
April 20, 2017 |
About JOUNCE THERAPEUTICS, INC. (NASDAQ:JNCE)
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator (ICOS), a protein on the surface of certain T cells found in a range of solid tumors. The Company has initiated JTX-2011 multi-arm Phase I/II clinical trial in patients with solid tumors. The Company is also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. The Company is developing JTX-4014, a fully human Immunoglobulin G 4 (IgG4) monoclonal antibody. JOUNCE THERAPEUTICS, INC. (NASDAQ:JNCE) Recent Trading Information
JOUNCE THERAPEUTICS, INC. (NASDAQ:JNCE) closed its last trading session up +0.45 at 24.84 with 201,613 shares trading hands.
